Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial

Janux Therapeutics Inc. (NASDAQ: JANX) is one of the best cancer stocks to invest in now. On February 17, Janux Therapeutics Inc. (NASDAQ:JANX) commenced patient dosing in the Phase 1 study of JANX011. The company has already dosed the first patient in the trial evaluating JANX011 for the treatment of autoimmune diseases.

The candidate drug is designed to enable deep and durable immune reset by targeting the depletion of CD19-expressing B cells in blood and tissue. Designed on the company’s ARM platform, it is intended to deliver sustained target B-cell depletion. The drug has already shown potential to achieve pharmacodynamic effects comparable to those of CAR-T therapies.

“Dosing the first participant with JANX011 marks an important milestone for Janux and the first clinical evaluation of our ARM platform,” said David Campbell, Ph.D., President and CEO, Janux Therapeutics. “While JANX011 is initially being developed for autoimmune diseases, the differentiated immune profile of the ARM platform may also have broader implications across CD19-expressing diseases, including hematologic malignancies.”

Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company developing novel, tumor-activated immunotherapies to treat cancer by maximizing T-cell targeting while minimizing toxicity. Using its proprietary TRACTr, TRACIr, and ARM platforms, Janux engineers bispecific molecules that selectively activate immune responses against solid tumors.